Kursinformationen (L&S)
- Tagestief / Hoch-
- 52W-Tief / Hoch314,000-373,600
- Jahrestief / Hoch253,900-404,900
Wichtigste Eigenschaften
Werbung
Schnellsuche von
Termine von argenx SE
- Mai4argenx SEQ1 2023 Earnings Release
- Jul27argenx SEQ2 2023 Earnings Release
- Okt27argenx SEQ3 2023 Earnings Release
Beschreibung
argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. argenx developed and is commercializing the neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others.
Pivot-Points (L&S)
NameWert
- Pivot-HBOP - R3360,800 €
- Pivot-Resist - R2353,600 €
- Pivot-High - R1349,600 €
- Pivotpunkt342,400 €
- Pivot-Low - S1338,400 €
- Pivot-Support - S2331,200 €
- Pivot-LBOP - S3327,200 €
Passender Service zu argenx SE
Webinar zu argenx SE
argenx SE Kurse
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit |
|---|---|---|---|---|---|
Wichtige Bewertungskennzahlen
Keine Kennzahlen vorhanden
Passende Produkte
Wertentwicklung (L&S)
-0,90 %
Intraday
3,60 %
1 Woche
6,40 %
1 Monat
-1,64 %
Seit Jahresbeginn
22,50 %
1 Jahr
185,42 %
3 Jahre
Peer Group
Novo-Nordisk AS 321,37 Mrd. €
Regeneron Pharmaceuticals Inc. 90,41 Mrd. $
Vertex Pharmaceuticals Inc. 80,53 Mrd. $
Moderna Inc. 56,66 Mrd. $
Seagen Inc. 37,99 Mrd. $
Alnylam Pharmaceuticals Inc 23,40 Mrd. $
Biomarin Pharmaceutical Inc. 17,06 Mrd. $
UCB S.A. 15,24 Mrd. €
ROYALTY PHARMA PLC Reg.Ord.Cl.A Shares DL-,0001 16,43 Mrd. $
Incyte Corp. 15,68 Mrd. $
